Cytiva expands Massachusetts biomanufacturing site

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Belchonock)
(Image: Getty/Belchonock)

Related tags: Cytiva, Massachusetts, Biotechs

The facility has been expanded to cater to the growing number of small- to mid-size biotechs looking to contract manufacture.

Cytiva announced that it had completed the renovation and expansion of its ‘Fast Trak’ contract biomanufacturing and process development site in Marlborough, US.

After the expansion, the facility now covers 60,00-square-feet of space and has the bioprocessing capacity to move from 10L to 2,000L scale. The services will be utilized to progress drug candidates through preclinical work onto Phase II.

Olivier Loeillot, SVP of BioProcess at Cytiva, explained that the facility will primarily serve small- to mid-size companies aiming to expedite processes, with biotech companies working to outsource manufacture to access expertise and capacity.

The upgraded site will feature an automated platform that is able to gather data to improve efficiency through the upstream and downstream process, the company stated.

LockeDrive 2
The expanded facility. Image: Cytiva

In addition to providing the contract services for biomanufacturing, the company outlined that any company using its Fast Trak facility would be able to place staff members in the plant, with Cytiva’s scientists providing training on the manufacturing process.

Cytiva was created earlier this year​, after Danaher acquired GE Life Sciences for $21bn (€18.6bn) and the resulting business unit took on the new moniker.

Since that time, the company has provided an update on its services for cell therapies​, by offering a shipping system specifically designed for this kind of treatment, as it pivots to the growing pipeline​ of cell and gene therapies.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more